Consider Lixiana for Patients Who Want a Once-Daily Direct Oral Anticoagulant

February 2017

Lixiana (LIKS-ee-ah-nah, edoxaban) will be the fourth direct oral anticoagulant (DOAC)...after Eliquis, Pradaxa, and Xarelto.

Lixiana is approved to reduce stroke risk due to atrial fib...and to treat venous thromboembolism (VTE).

It's marketed in the U.S. under the brand name Savaysa.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Interactions Follow These Rules of Thumb to Manage Drug Interactions
Smoking Cessation Expect Less Concern Over Psychiatric Effects With Champix
COPD Expect Fewer Inhaled Steroids to Be Used for COPD
Anticoagulants Consider Lixiana for Patients Who Want a Once-Daily Direct Oral Anticoagulant
Interactions Watch for Statin Interactions With Pradaxa
Antihistamines Expect to See Blexten and Rupall Rxs for Patients With Allergies
Respiratory & Allergy Think of OTC Flonase Allergy Relief as Similar to Nasacort Allergy 24HR
Muscle Relaxants Recommend Limiting Use of Muscle Relaxants to 7 Days for Acute Low Back Pain
NSAIDs Ease Concerns About Using NSAIDs After Most Fractures
Hypotension Consider Med Causes and Suggest Nondrug Measures in Orthostatic Patients
Side Effects Address Taste Disturbances to Prevent Med Adherence Issues
Renal & Urology Explain When Alpha-Blockers May Be Helpful for Kidney Stones